Octal Credit Cap (538894)
Asset PlayScore breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹32.89 |
| Market Cap | ₹17.07 Cr |
| P/E Ratio | 0 |
| ROCE | -2.45% |
| ROE | 0.65% |
| Dividend Yield | 0% |
| Profit Growth | 0% |
| Debt/Equity | — |
| Sales Growth | 0% |
| 52-Week Range | ₹17.91 — ₹32.89 |
| Sector | Finance |
| Book Value | ₹21.84 |
Strengths
- Book value of ₹21.84 provides some tangible asset backing against downside.
- No reported debt (Debt/Equity N/A) may imply a conservative balance sheet.
- Piotroski F-Score of 6/9 suggests acceptable basic financial health.
- Near 52-week high of ₹32.89 shows some market interest or momentum.
Concerns
- Zero sales and a net loss in the latest quarter indicate no active income generation.
- ROE of 0.65% and negative ROCE of -2.45% reflect severe capital misallocation.
- P/B of 1.51 means investors pay a 51% premium over book for a business earning almost nothing.
- No dividend, no growth, and no promoter holding disclosure leaves little for minority shareholders.
AI Analysis
Let's look at Octal Credit Cap through a Graham-Buffett lens. This is a micro-cap NBFC with a market cap of just ₹17 crore, trading at ₹32.89 against a book value of ₹21.84. That means I'm paying a 51% premium to net assets for a business that earns a paltry 0.65% return on equity. The latest quarter shows zero sales and a small net loss, and the ROCE is deeply negative at -2.45%. In plain terms, this company is not generating any meaningful return on the capital employed in the business. There is no evidence of a moat, no growth in sales or profits, and no dividend to compensate me while I wait. The Piotroski F-Score of 6/9 suggests the balance sheet isn't deteriorating badly, but that is faint praise. The only apparent support is the book value, which gives some asset-backing, but at 1.51 times book, Mr. Market is already demanding a premium for a subpar earner. A true Graham investor would demand a margin of safety: either a price well below conservative book value, or evidence of improving returns. We have neither. I see no competitive advantage in a non-banking financial company with no revenue momentum and negative operating profitability. This strikes me as an asset play at best, but not a bargain at this price. I'd rather wait for a far lower price, or clear proof of a turnaround in earnings, before committing any capital. As Buffett says, it's far better to buy a wonderful business at a fair price than a mediocre business at a premium.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer